Companion Diagnostics Market

The companion diagnostics market is projected to reach USD 11.57 billion by 2031, from USD 6.31 billion in 2026, with a CAGR of 12.9%. The market is mainly driven by the increasing adoption of precision medicine, oncology-focused targeted therapies, and biomarker-driven treatment selection. Elevated cancer incidence, broader use of NGS and PCR-based testing, drug–diagnostic co-development, and regulatory emphasis on identifying patients most likely to benefit from specific therapies are other factors contributing to market growth.

The companion diagnostics market is moderately consolidated, with leading players such as F. Hoffmann-La Roche AG (Switzerland), Agilent Technologies, Inc. (US), QIAGEN (Netherlands), Thermo Fisher Scientific Inc. (US),  Guardant Health, Inc (US), Danaher (US), Abbott (US), and Illumina, Inc. (US). These companies are strengthening their market positions through FDA-approved CDx assays, oncology testing platforms, pharma partnerships, NGS-based companion diagnostic development, and geographic expansion.

To know about the assumptions considered for the study download the pdf brochure

F. Hoffmann-La Roche AG is a leading participant in the companion diagnostics market, supported by its strong oncology diagnostics portfolio, broad molecular and tissue-based testing capabilities, and close alignment with targeted therapy development. The company offers companion diagnostic solutions across IHC, ISH, PCR, and sequencing-based workflows. Roche’s strength is further supported by its integrated pharmaceutical and diagnostics model, enabling effective biomarker-driven therapy selection and drug–diagnostic co-development.

Agilent Technologies, Inc. is a major player in the companion diagnostics market, particularly in tissue-based oncology testing. Through its Dako-branded pathology solutions, the company provides IHC and ISH-based assays used for biomarker detection and targeted therapy selection. Agilent’s strong installed base in pathology laboratories, regulatory experience in CDx assay development, and collaborations with pharmaceutical companies support its position in the global companion diagnostics market.

Market Ranking

The companion diagnostics market is characterized by moderate to high consolidation, with leading players accounting for a significant share of the total market revenue in 2025. The top four companies collectively accounted for nearly 38–42% of the global market, supported by their strong regulatory expertise, broad oncology testing portfolios, pharmaceutical partnerships, and established molecular diagnostics infrastructure. These companies continue to strengthen their positions through FDA-approved companion diagnostic assays, biomarker-focused collaborations, technology advancements, and geographic expansion initiatives.

F. Hoffmann-La Roche AG maintains a leading position in the companion diagnostics market through its integrated diagnostics and pharmaceutical ecosystem, extensive oncology biomarker portfolio, and strong capabilities across PCR, IHC, ISH, and sequencing-based testing. Agilent Technologies, Inc. is a prominent player in tissue-based companion diagnostics through its Dako pathology portfolio, offering companion diagnostic assays and advanced biomarker testing solutions for targeted oncology therapies. QIAGEN N.V. provides molecular testing solutions, PCR technologies, and therascreen companion diagnostic assays that support precision medicine and biomarker-guided treatment decisions. Thermo Fisher Scientific Inc. offers NGS platforms, molecular diagnostic technologies, assay development capabilities, and clinical research solutions that support pharmaceutical companies in companion diagnostic development and commercialization workflows. The remainder of the market is fragmented across regional diagnostic developers, specialty molecular diagnostics companies, precision oncology firms, and emerging biomarker testing providers. These companies compete through niche biomarker expertise, innovative sequencing technologies, liquid biopsy capabilities, customized assay development services, and collaborations with pharmaceutical and biotechnology companies for targeted therapy-linked diagnostic development.

Related Reports:

Companion Diagnostics Market by Product (Assays, Kits, & Reagents, Instruments, Software), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung, Colorectal Cancer, CVD, Infectious), Drug Class (MAB, Cell & Gene Therapy) - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]